Dosimetry for 131I-MIBG Therapies in Metastatic Neuroblastoma, Phaeochromocytoma and Paraganglioma

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2010 Feb 25

PMID 20179922

Citations 7

Authors

Ferdinand Sudbrock

Matthias Schmidt

Thorsten Simon

Wolfgang Eschner

Frank Berthold

Harald Schicha

Affiliations

Soon will be listed here.

Abstract

Purpose: Radiation dosimetry is a basic requirement for targeted radionuclide therapies (TRT) which have become of increasing interest in nuclear medicine. Despite the significant role of the radiopharmaceutical (131)I-metaiodobenzylguanidine (MIBG) for the treatment of metastatic neuroblastoma, phaeochromocytoma and paraganglioma details for a reliable dosimetry are still sparse. This work presents our procedures, the dosimetric data and experiences with TRT using (131)I-MIBG.

Methods: A total of 21 patients were treated with (131)I-MIBG between 2004 and 2008 according to a clearly defined protocol. Whole-body absorbed doses were determined by a series of scintillation probe readings for all 21 cases. Tumour absorbed doses were calculated on the basis of quantitative imaging for an entity of 25 lesions investigated individually using the region of interest (ROI) technique based on five scans each.

Results: Typical whole-body absorbed doses are found in the region of 2 Gy (range: 1.0-2.9 Gy) whereas tumour absorbed doses in turn cover a span between 10 and 60 Gy. Nonetheless this variation of tumour absorbed doses is comparatively low.

Conclusion: The trial protocol in use is a substantial advancement in terms of reliable dosimetry. A clearly defined modus operandi for MIBG therapies should involve precisely described dosimetric procedures, e.g. a minimum of 20 whole-body measurements using a calibrated counter and at least four gamma camera scans over the whole period of the inpatient stay should be carried out. Calculation of tumour volumes is accomplished best via evaluation of SPECT and CT images.

Citing Articles

Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice.

Fischer T, Dietlein F, Bongartz D, Klehr M, Zimmermanns B, Schmidt M Int J Mol Sci. 2024; 25(19).

PMID: 39409066 PMC: 11476365. DOI: 10.3390/ijms251910737.

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning.

Sapienza M, Willegaignon J Clinics (Sao Paulo). 2019; 74:e835.

PMID: 31365617 PMC: 6644503. DOI: 10.6061/clinics/2019/e835.

Dosimetry-based high-activity therapy with I-metaiodobenzylguanidine (I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma.

Genolla J, Rodriguez T, Minguez P, Lopez-Almaraz R, Llorens V, Echebarria A Eur J Nucl Med Mol Imaging. 2019; 46(7):1567-1575.

PMID: 30838430 DOI: 10.1007/s00259-019-04291-x.

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Falzone L, Salomone S, Libra M Front Pharmacol. 2018; 9:1300.

PMID: 30483135 PMC: 6243123. DOI: 10.3389/fphar.2018.01300.

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

Kraal K, van Dalen E, Tytgat G, Van Eck-Smit B Cochrane Database Syst Rev. 2017; 4:CD010349.

PMID: 28429876 PMC: 6478145. DOI: 10.1002/14651858.CD010349.pub2.

References

Unak P, Cetinkaya B . Absorbed dose estimates at the cellular level for 131I. Appl Radiat Isot. 2005; 62(6):861-9. DOI: 10.1016/j.apradiso.2004.07.013. View

Vaidyanathan G, Zalutsky M . No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot. 1993; 44(3):621-8. DOI: 10.1016/0969-8043(93)90179-e. View

Kara Gedik G, Hoefnagel C, Bais E, Olmos R . 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2007; 35(4):725-33. DOI: 10.1007/s00259-007-0652-6. View

Bolster A, Hilditch T, Wheldon T, Gaze M, Barrett A . Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children. Br J Radiol. 1995; 68(809):481-90. DOI: 10.1259/0007-1285-68-809-481. View

Simon T, Hero B, Bongartz R, Schmidt M, Muller R, Berthold F . Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol. 2006; 182(7):389-94. DOI: 10.1007/s00066-006-1498-8. View

Klingebiel T, Treuner J, Ehninger G, Keller K, Dopfer R, FEINE U . [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol. 1989; 25(2):143-8. DOI: 10.1007/BF00692356. View

Schmidt M, Simon T, Hero B, Schicha H, Berthold F . The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008; 44(11):1552-8. DOI: 10.1016/j.ejca.2008.03.013. View

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F . Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. 2006; 45(4):145-51. View

Kushner B . Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004; 45(7):1172-88. View

10.

Hoefnagel C, VOUTE P, de Kraker J, MARCUSE H . Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med. 1987; 28(3):308-14. View

11.

Tang H, da Silva A, Matthay K, Price D, Huberty J, Hawkins R . Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med. 2001; 42(2):237-47. View

12.

Fielding S, Flower M, Ackery D, Kemshead J, Lashford L, Lewis I . Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med. 1991; 18(5):308-16. DOI: 10.1007/BF02285457. View

13.

Flower M, Fielding S . Radiation dosimetry for 131I-mIBG therapy of neuroblastoma. Phys Med Biol. 1996; 41(10):1933-40. DOI: 10.1088/0031-9155/41/10/006. View

14.

Flux G, Guy M, Papavasileiou P, South C, Chittenden S, Flower M . Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm. 2003; 18(1):81-7. DOI: 10.1089/108497803321269359. View

15.

Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H . Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002; 29(12):1581-7. DOI: 10.1007/s00259-002-0973-4. View

16.

Chrisoulidou A, Kaltsas G, Ilias I, Grossman A . The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007; 14(3):569-85. DOI: 10.1677/ERC-07-0074. View

17.

ODonoghue J, Sgouros G, Divgi C, Humm J . Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med. 2000; 41(3):538-47. View

18.

Sgouros G . Toward patient-friendly cell-level dosimetry. J Nucl Med. 2007; 48(4):496-7. DOI: 10.2967/jnumed.106.036749. View

19.

Bolster A, Hilditch T, Wheldon T . Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG. J Nucl Med. 1995; 36(8):1530-1. View

20.

Sudbrock F, Boldt F, Kobe C, Hammes J, Eschner W, Schicha H . [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures]. Nuklearmedizin. 2009; 48(1):17-25. View